Price
No data yet.
Social Signal Score
Revenue
$129.46M+442.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chaim Indig
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 1,789
- Beta
- 0.84
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.95
Financials
Revenue
$129.46M+442.3%Net Income
$4.56MEBITDA
$7.61M+882.1%Free Cash Flow
$17.84MEPS (diluted)
$0.03Shares Outstanding (diluted)
62.46M+121.5%Operating Expenses
$68.67MCash & Debt
$72.94MReturn of Capital
$0.00Revenue by Segment (annual)
$480.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $480.59M | $2.31M | $0.04 |
| 2025 | $419.81M | $-58.53M | $-1.02 |
| 2024 | $356.30M | $-136.88M | $-2.51 |
| 2023 | $280.91M | $-176.15M | $-3.36 |
| 2022 | $213.23M | $-118.16M | $-2.37 |
| 2021 | $148.68M | $-27.29M | $-0.69 |
| 2020 | $124.78M | $-20.29M | $-1.00 |
| 2019 | $99.89M | $-15.06M | $-8.16 |
| 2018 | $79.83M | $-18.19M | $-11.82 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.06
- Implied price
- $1.02
- Return from $11.88
- -38.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.51 — -95.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -48.8% | -46.4% | -44.5% | -42.7% | -41.2% |
| 3.0% | -46.2% | -43.7% | -41.6% | -39.8% | -38.2% |
| 8.0% | -43.6% | -41.0% | -38.8% | -36.9% | -35.2% |
| 13.0% | -40.9% | -38.2% | -36.0% | -33.9% | -32.2% |
| 18.0% | -38.3% | -35.5% | -33.1% | -31.0% | -29.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
87Social Signal Score
Mentions (3)
- Newszacks.com·4h ago·Neutral
Phreesia (PHR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended July 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·5h ago·Negative
Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates Phreesia (PHR) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.01 per share a year ago.
View source ↗ - Newsmarketbeat.com·5h ago·Negative
Phreesia Q2 Earnings Call Highlights Phreesia NYSE: PHR reported second-quarter fiscal 2027 revenue growth and continued profitability expansion, while maintaining its full-year revenue and adjusted EBITDA outlook. The company said it generated positive operating and free cash flow for the ninth consecutive quarter and used its cash generation and available cash to reduce debt principal by more than $23 million.
View source ↗
Earnings
Mon, Dec 14(in 3 months)
Consensus estimate $0.12 per share
Typical surprise +44.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Sep 2$0.03 vs $0.09miss
- Wed, May 27$0.05 vs $0.02beat
- Mon, Mar 30$0.02 vs $0.07miss
- Mon, Dec 8$0.10 vs $-0.00beat
- Thu, Sep 4$0.01 vs $-0.07beat
- Wed, May 28$-0.07 vs $-0.13beat
Estimates and results for PHR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PHR officers and directors.
- Bought
- $28.8m
- Sold
- $1.9m
6 trades
36 trades
- Hui Yvonnesold
- Egbuonu-davis Lisasold
- Hui Yvonnesold
- Egbuonu-davis Lisasold
- Hui Yvonnesold
- Hoffman Allison Csold
- Hui Yvonnesold
- Hui Yvonnesold
58 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.